Clinical Trial

Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance

Completed
View on ClinicalTrials.gov →
Summary
Through an observational clinical study, partly prospective and partly retrospective, based on the collection of clinical data and on in vitro experimental analyses carried out on residual biological samples obtained during routine clinical procedures, it is proposed to identify predictive biomarkers of in vivo response to first-line therapies.
Trial Details
NCT Number NCT07585331
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions AL Amyloidosis
Enrollment 250 participants
Start Date 2022-01-13
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-13